Benzinga
FDA Approves TherapeuticsMD’s Low Dose Bijuva
TherapeuticsMD Inc (NASDAQ: TXMD) is trading sharply higher after it announced that the FDA approved a low dose version of Bijuva, an oral hormone therapy to treat women with vasomotor symptoms due to menopause. In a regulatory filing, TherapeuticsMD said that on December 28, the agency cleared its supplemental marketing application for Bijuva, seeking approval for the capsule at the 0.5 mg/100 mg dose level. Related Link: TherapeuticsMD, Amneal Settle US Patent Litigation For Bijuva. The plans